Targeted therapies for non-small-cell lung cancer: Biology, rationale, and preclinical results from a radiation oncology perspective

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 2 SUPPL., 2004, Pages S27-S38

  Raben, David ^a,b   Helfrich, Barb ^a   Bunn Jr , Paul A ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Epidermal growth factor receptor (EGFR); Non small cell lung cancer (NSCLC); Targeted therapy

Indexed keywords

CELLS; CHEMOTHERAPY; GROWTH KINETICS; RADIOTHERAPY; TUMORS;

CELL GROWTH; EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR);

ONCOLOGY;

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; GEMCITABINE; GENE EXPRESSION MODULATOR 231; IMC 1 C 11; M 225; M 528; MATUZUMAB; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 806; PACLITAXEL; PLACEBO; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VATALANIB; Y 10;

ACNE; ACNEIFORM RASH; ANGIOGENESIS; BIOLOGY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER THERAPY; DIARRHEA; DRUG BINDING; DRUG RESPONSE; DRUG TOLERABILITY; ENZYME ACTIVATION; GENETIC TRANSCRIPTION; HORMONAL THERAPY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NONHUMAN; ONCOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; RASH; REVIEW; SIGNAL TRANSDUCTION;

EID: 2342557044     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.01.054     Document Type: Article

References (97)

1. Jemal A., Thomas A., Murray T. Cancer statistics, 2002. CA Cancer J Clin. 52:2002;23-47
2. Schiller J. Current standards of care in small-cell and non-small-cell lung cancer. Oncology. 61:2001;3-13
3. Curran W, Scott C, Langer C, et al. Phase III comparison of sequential vs concurrent chemoradiation for PTS with unresected stage III non-small cell lung cancer (NSCLC): Initial report of Radiation Therapy Oncology Group (RTOG) 9410 (Abstr. 1891). Proc Am Soc Clin Oncol 2000;19:484a
4. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 17:1999;2692-2699
5. Koening T., Munden R., Erasmus J., et al. Radiation injury of the lung after three-dimensional conformal radiation therapy. Am J Roentgenol. 178:2002;1383-1388
6. Raymond R., Faivre S., Armand J. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs. 60:2000;15-23
7. Baselga J, Herbst R, LoRusso P, et al. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: Evidence of activity and good tolerability (Abstr. 686). Proc Am Soc Clin Oncol 2000;19:177a
8. Baselga J, Yano S, Giaccone G, et al. Initial results from a phase II trial of ZD1839 (Iressa) as second and third-line monotherapy for patients with advanced non-small cell lung cancer (IDEAL 1). Paper presented at: Annual meeting of American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer; October 29-November 2, 2001; Miami Beach, Florida. Abstract 630a
9. Dent P., Reardon D., Park J., et al. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell. 10:1999;2493-2506
10. Gorski D., Beckett M., Jaskowiak N., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59:1999;3374-3378
11. Ciardiello F., Caputo R., Bianco R., et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res. 7:2001;1459-1465
12. Petit A., Rak J., Hung M., et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 151:1997;1523-1530
13. Giaccone G, Johnson D, Manegold C, et al. A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT 1) (Abstr. 40). Ann Oncol 2002;13 (Suppl 5):2
14. Johnson D, Herbst R, Giaccone G, et al. ZD1839 ('Iressa') in combination with paclitaxel & carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC): Results from a phase III clinical trial (INTACT 2) (Abstr. 4680). Ann Oncol 2002;13 (Suppl 5):127
15. Riese D.I., Stern D. Specificity within the EGF family/erbB receptor family signaling network. BioEssay. 20:1998;41-48
16. Beerli R., Hynes N. Epidermal growth factor-related peptides activate distinct subsets of erbB receptors and differ in their biological activities. J Biol Chem. 271:1996;6071-6076
17. Riese D.I., Van Raaij T., Plowman G., et al. Betacellulin activates the epidermal growth factor receptor and ErbB4 and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-3. Oncogene. 12:1996;345-353
18. Monilola A., Olayioye R., Neve H., et al. The ErbB signaling network Receptor heterodimerization in development of cancer. EMBO J. 19:2000;3159-3167
19. French A., Tadaki D., Niyogi S., et al. Intracellular trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand interaction. J Biol Chem. 270:1995;4334-4340
20. Waterman H., Sabani I., Yarden Y. Alternative intracellular routing of ErbB receptors may determine signaling potency. J Biol Chem. 273:1998;13819-13827
21. Shoelson S. SH2 and PTB domain interactions in tyrosine kinase signal transduction. Curr Opin Chem Biol. 1:1997;227-234
22. Sudol M. From Src homology domains to other signaling modules Proposal of the 'protein recognition code'. Oncogene. 17:1998;1469-1474
23. Al Moustafa A.-E., Yen L., Benlimane N., et al. Regulation of E-cadherin/catenin complex patterns by epidermal growth factor receptor modulation in human lung cancer cells. Lung Cancer. 37:2002;49-56
24. Bogdan S., Klambt C. Epidermal growth factor receptor signaling. Curr Biol. 10:2001;R292-R295
25. Datta S., Brunet A., Greenberg M. Cellular survival A play in three Akts. Genes Dev. 15:1999;2905-2927
26. Filippa N., Sable C., Hemmings B. Mechanism of protein kinase B activation by cyclic AMP-dependent protein kinase. Mol Cell Biol. 19:1999;4989-5000
27. Yano S., Tokumitsu H., Soderling T. Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway. Nature. 396:1998;584-587
28. Datta S., Dudek H., Tao X., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 91:1997;231-241
29. Cardone M., Roy N., Stennicke H., et al. Regulation of cell death protease caspase-9 by phosphorylation. Science. 282:1998;1318-1321
30. Brognard J., Clark A., Yucheng N. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 61:2001;3986-3997
31. Soria J.-C., Lee H.-Y., Lee J. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res. 8:2002;1178-1184
32. Buettner R., Mora L., Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 8:2002;945-954
33. Blaudschum R., Brenneisen P., Wlaschek M., et al. The first peak of the UVB irradiation-dependent biphasic induction of vascular endothelial growth factor (VEGFR) is due to phosphorylation of the epidermal growth factor receptor and independent of autocrine transforming growth factor alpha. FEBS Lett. 474:2000;195-200
34. Brekken R., Thorpe P. VEGF-VEGF receptor complexes as markers of tumor vascular endothelium. J Control Release. 74:2001;173-181
35. Veikkola T., Karkkainen M., Claesson-Welsh L., et al. Regulation of angiogenesis via endothelial growth factor receptors. Cancer Res. 60:2000;203-212
36. McMahnon G. VEGF receptor signaling in tumor angiogenesis. Oncologist. 5:2000;3-10
37. Brekken R., Overholser J., Stastny J., et al. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal antiVEGF antibody blocks tumor growth in mice. Cancer Res. 60:2000;5117-5124
38. Cox G., Jones J., Walker R., et al. Angiogenesis and non-small cell lung cancer. Lung Cancer. 27:2000;81-100
39. Slamon D., Brandt R., Ciardiello F., et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 19:1995;183-232
40. Woodburn J. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 82:1999;241-250
41. Salomon D., Clark G., Wong S., et al. Human breast cancer Correlation of relapse and survival with amplification of the HER2/neu oncogene. Science. 235:1987;177-182
42. Friess H., Kleeff J., Korc M., et al. Molecular aspects of pancreatic cancer and future perspectives. Dig Surg. 16:1999;281-290
43. Porebska I., Harlozinska A., Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumor Biol. 21:2000;105-115
44. Grandis J., Melhem M., Gooding W., et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 90:1998;824-832
45. Brabender J., Danenberg K., Metzger R., et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Cancer Res. 7:2001;1850-1855
46. Yi E., Harclerod D., Gondo M., et al. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. Mod Pathol. 10:1997;142-148
47. Paulettu G., Dandekar S., Rong H., et al. Assessments of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer. A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 18:2000;3651-3664
48. Bunn P., Helfrich B., Soriano A., et al. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res. 7:2001;3239-3250
49. Shimizu N., Wang Y., Minoshima S., et al. Detection of epidermal growth factor receptor gene amplication in human squamous cell carcinomas using fluorescence in situ hybridization. Jpn J Cancer Res. 85:1994;567-571
50. Akimoto T., Hunter N., Buchmiller L., et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res. 5:1999;2884-2890
51. Dent P., Reardon D., Park J., et al. Radiation-induced release of transforming growth factor-alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell. 3:1997;1943-1948
52. Haung S., Bock J., Harari P., et al. Epidermal growth factor receptor blockage with C225 modulates proliferation, apoptosis and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59:1999;1935-1940
53. Peng D., Fan Z., Lu Y., et al. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res. 56:1996;3666-3669
54. Fan Z., Shang B., Lu Y., et al. Reciprocal changes in p27 (Kip1) and p21 (Cip1) in growth inhibition medicated by blockade or overstimulation of epidermal growth factor receptors. Clin Cancer Res. 3:1997;1943-1948
55. Mendelsohn J. Blockade of receptors for growth factors An anticancer therapy. Clin Cancer Res. 6:2000;747-753
56. Helfrich B, Raben D, Chan D, et al. C225 anti-epidermal growth factor receptor (EGFR) monoclonal antibody sensitizes human non-small cell lung cancer to both radiation and chemotherapy cytotoxicity in vitro and in vivo. Paper presented at: 43rd Annual Meeting of American Society of Therapeutic Radiology and Oncology; November 4-8, 2001; San Francisco, California
57. Milas L., Mason K., Hunter N., et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 6:2000;701-708
58. Huang S., Harari P. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas Inhibition of damage repair cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res. 6:2000;2166-2174
59. Lynch D., Yang X. Therapeutic potential of ABX-EGF A fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol. 29:2002;47-50
60. Sampson J., Crotty L., Lee S., et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A. 97:2000;7503-7508
61. Figlin R., Belldegrun J., Crawford J., et al. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer Phase 1 clinical results (Abstr. 35). Proc Am Soc Clin Oncol. 21:2002;10a-11
62. Wikstrand C., Reist C., Archer G., et al. The class III variant of the epidermal growth factor receptor (EGFRvIII) Characterization and utilization as an immunotherapeutic target. J Neurovirol. 4:1998;148-158
63. Nishikawa R, Ji X, Harmon R, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 1994;91:7727-7731
64. Tang C., Gong X., Moscatello D., et al. A mutant epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res. 60:2000;3081-3087
65. Luwor R., Johns T., Murone C., et al. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild type EGFR. Cancer Res. 60:2000;3081-3087
66. Mishima K., Johns T., Luwor R., et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (MAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res. 61:2001;7703-7705
67. Hoffman T., Hafner D., Ballo I.I., et al. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Anticancer Res. 17:1997;4419-4426
68. Ciardiello F, Caputo V, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003:9:1546-1556
69. Wakeling A., Barker A., Davies D. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res Treat. 38:1996;67-73
70. Levitt M., Koty P. Tyrosine kinase inhibitors in preclinical development. Invest New Drugs. 17:1999;213-226
71. Bridges A., Cody D., Zhou H., et al. Enantioselective inhibition of the epidermal growth factor receptor tyrosine kinase by 4-(a-phenethylamino) quinazolines. Bioorg Mol Chem. 3:1995;1651-1656
72. Levitzki A., Gazit A. Tyrosine kinase inhibitors An approach to drug development. Science. 267:1995;1782-1788
73. Klohs W., Fry D., Kraker A. Inhibitors of tyrosine kinases. Curr Opin Oncol. 9:1997;562-568
74. Levitzki A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol Ther. 82:1999;231-239
75. Traxler P., Furet P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol Ther. 82:1999;195-206
76. Lidhtner R., Menrad A., Sommer A., et al. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res. 61:2001;5790-5795
77. Ciardiello F., Caputo R., Bianco R., et al. Antitumor effect and potentiation of cytotoxic drugs Activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res. 6:2000;2053-2063
78. Sirotnak F., Zakowski M., Miller V., et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 6:2000;4885-4892
79. Raben D, Helfrich B, Chan D, et al. The effects of ZD1839 (Iressa) on cell signaling processes and its growth effects with radiation and chemotherapy in human non-small cell lung cancer cell in vitro. Paper presented at: Annual Meeting of American Association of Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer; October 29-November 2, 2001; Miami Beach, Florida
80. Albanell J., Rojo F., Baselga J. Pharmacodynamic with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin Oncol. 28:2001;56-66
81. Moulder S., Yakes F., Muthuswamy S., et al. Epidermal growth factor receptor (HERI) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 61:2001;8887-8895
82. Anido J, Albanell J, Rojo F, et al. Inhibition by ZD1839 (Iressa) of epidermal growth factor (EGF) and heregulin induced signaling pathways in human breast cancer cells (Abstr. 1712). Proc Am Soc Clin Oncol, 2001;20:429a
83. Moasser M., Basso A., Averbuch S., et al. The tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2-driven signaling and suppress the growth of HER2-overexpressing tumor cells. Cancer Res. 61:2001;7184-7188
84. Huang S., Li J., Armstrong E., et al. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor inhibition by ZD1839 (Iressa). Cancer Res. 62:2002;4300-4306
85. Bianco R, Bianco C, Caputo R, et al. Selective inhibition of the epidermal growth factor receptor tyrosine kinase (EGFR-TK) by ZD1839 (Iressa) potentiates the antitumor effects of ionizing radiation. Paper presented at: 93rd Annual Meeting of American Association of Cancer Research; April 6-10, 2002; San Francisco, California.
86. Williams K., Telfer B., Stratford I., et al. ZD1839 (Iressa), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer. 86:2002;1157-1161
87. TM, OSI-774) in human carcinoma cell lines. Paper presented at: 94th Annual Meeting of American Association of Cancer Research; July 11-14, 2003; Washington, DC
88. Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum based chemotherapy in patients advanced EGFR expressing, non-small cell lung cancer (NSCLC) (Abstr. 1235). Proc Am Soc Clin Oncol 2001;20:310a
89. Rao G., Murray S., Ethier S. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys. 48:2000;1519-1528
90. Nicholson R, Harper M, Hutcheon I, et al. ZD1839 (Iressa) improves the antitumor activity of tamoxifen (Novaldex) in antihormone-responsive breast cancer cell. Paper presented at: Annual Meeting of American Association of Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer; October 29-November 2, 2001; Miami Beach, Florida
91. Viloria-Petit A., Crombet T., Jothy S., et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo. Cancer Res. 61:2001;5090-5101
92. Chakravarti A., Loeffler J., Dyson N. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 62:2002;200-207
93. Albanell J., Baselga J. Unraveling resistance to trastuzumab (Herceptin) Insulin-like growth factor I receptor, a new suspect. J Natl Cancer Inst. 93:2001;1830-1832
94. Brandt R, O'Reilly T, Cozens R, et al. Combined inhibition of EGF-receptor and VEGF-receptor kinases produces high anti-tumor efficacy against experiment cancer. Paper presented at: 93rd Annual Meeting of American Association of Cancer Research; April 6-10, 2002; San Francisco, California
95. Tortora G., Caputo R., Damiano V., et al. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A and the epidermal growth factor inhibitor Iressa causes co-operative antitumor and anti-angiogenic activity. Clin Cancer Res. 7:2001;4156-4163
96. Tortora G., Damiano V., Bianco C., et al. The Rialpha subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF receptor. Oncogene. 14:1997;923-928
97. Bianco C., Bianco R., Tortora G., et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor antibody C225 plus Type 1 protein kinase A antisense oligonucleotide. Clin Cancer Res. 6:2000;4343-4350